Source:http://linkedlifedata.com/resource/pubmed/id/19288103
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2009-9-17
|
| pubmed:abstractText |
Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce. We report our results using the LMB protocol on Korean adult BL patients. Thirty-eight newly diagnosed BL patients were treated with the LMB protocol; 29 males and nine females with a median age of 47 years (range 18-70) were analyzed, and 14 (36.8%) patients had central nervous system or bone marrow involvement. After the induction phase, 28 patients achieved complete response (CR, 73.7%) and five showed partial response (PR, 13.2%). Among those achieving CR, only four showed relapse. All of the non-CR patients died, including five PR and one with progressive disease. The other four patients died because of infection after the first course of induction. The progression-free and overall estimated survival at 5 years was 74.99% and 68.10%, respectively. Of the 12 patients who died, the median survival was 4.43 months (95% confidence interval 1.43-7.43 months). Thus, most deaths occurred shortly after diagnosis, and four patients older than 58 years died after the first induction cycle. Most early deaths were caused by treatment-related morbidity and failure to achieve complete response. B symptoms, advanced age, bone marrow involvement, and St. Jude/Murphy stage IV classification were significantly associated with poor overall survival. In conclusion, the LMB protocol was effective for Korean adult BL patients. However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1432-0584
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
88
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1099-106
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19288103-Adolescent,
pubmed-meshheading:19288103-Adult,
pubmed-meshheading:19288103-Aged,
pubmed-meshheading:19288103-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19288103-Burkitt Lymphoma,
pubmed-meshheading:19288103-Cyclophosphamide,
pubmed-meshheading:19288103-Cytarabine,
pubmed-meshheading:19288103-Disease-Free Survival,
pubmed-meshheading:19288103-Doxorubicin,
pubmed-meshheading:19288103-Drug Evaluation,
pubmed-meshheading:19288103-Etoposide,
pubmed-meshheading:19288103-Female,
pubmed-meshheading:19288103-Hematologic Diseases,
pubmed-meshheading:19288103-Humans,
pubmed-meshheading:19288103-Kaplan-Meier Estimate,
pubmed-meshheading:19288103-Korea,
pubmed-meshheading:19288103-Male,
pubmed-meshheading:19288103-Methotrexate,
pubmed-meshheading:19288103-Middle Aged,
pubmed-meshheading:19288103-Prednisone,
pubmed-meshheading:19288103-Prognosis,
pubmed-meshheading:19288103-Proportional Hazards Models,
pubmed-meshheading:19288103-Retrospective Studies,
pubmed-meshheading:19288103-Risk Factors,
pubmed-meshheading:19288103-Sepsis,
pubmed-meshheading:19288103-Treatment Outcome,
pubmed-meshheading:19288103-Vincristine,
pubmed-meshheading:19288103-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
|
| pubmed:affiliation |
Division of Hematology-Oncology, Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, South Korea.
|
| pubmed:publicationType |
Journal Article
|